Приказ основних података о документу

dc.creatorBajraktarević, Azra
dc.creatorMehmedagić, Aida
dc.creatorVučićević, Katarina
dc.creatorKulić, Mehmed
dc.creatorMiljković, Branislava
dc.date.accessioned2019-09-02T11:54:00Z
dc.date.available2019-09-02T11:54:00Z
dc.date.issued2016
dc.identifier.issn0001-6837
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/2667
dc.description.abstractBeing a narrow therapeutic index drug, digoxin may cause harm if dosed without regular measurements of serum levels. Due to various limitations in its dosing, different challenges still exist in clinical practice. This study aimed to assess digoxin though concentrations after different regimens in adult and elderly patients, and to identify predictor variables for the ratio of given dose and digoxin trough level. This was prospective open-label study. Digoxin was administered per os as 0.125. or 0.25 mg during different continuous and interrupted dosage regimens. Study protocol allowed an additional therapy according to contemporary guidelines. Digoxin concentrations were determined using Abbott AxSYM Digoxin II assay in trough samples (1-3 per patient) after 3-4 weeks stable regimen. In total, 191 concentrations (104 patients) were analyzed. Digoxin weekly dose was in range 0.375-1.75 mg. On average, we observed slightly lower digoxin levels in 1-117 patients. Results showed that in patients receiving digoxin with interrupted dosage regimen post pause digoxin level was statistically significantly lower than pre-pause (p lt 0.05). Based on multiple linear regression, the ratio of given dose and trough concentration was mainly predicted by clearance creatinine, and to lesser extent by patient's ideal body weight. Interrupted dosing schedule shows greater variability in drug levels comparing to continuous dosing, and it additionally causes difficulties in reaching and maintaining steady trough levels between doses. Hence, individualization of dosing regimen should he carefully guided based on target levels and not solely on clinical signs and symptoms.en
dc.publisherPolskie Towarzystwo Farmaceutyczne, Warsaw
dc.relationFaculty of Pharmacy, University of Sarajevo, Bosnia and Herzegovina
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175023/RS//
dc.rightsrestrictedAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.sourceActa Poloniae Pharmaceutica - Drug Research
dc.subjectDigoxinen
dc.subjectDosing regimenen
dc.subjectPharmacokineticsen
dc.subjectTherapeutic drug monitoringen
dc.titleThe posology and trough concentrations of digoxin in adult and elderly patientsen
dc.typearticle
dc.rights.licenseBY-NC
dcterms.abstractМехмедагић, Aида; Бајрактаревић, Aзра; Миљковић, Бранислава; Кулић, Мехмед; Вучићевић, Катарина;
dc.citation.volume73
dc.citation.issue5
dc.citation.spage1361
dc.citation.epage1368
dc.citation.other73(5): 1361-1368
dc.citation.rankM23
dc.identifier.wos000394080700027
dc.identifier.pmid29638076
dc.identifier.scopus2-s2.0-84990967227
dc.identifier.rcubhttps://hdl.handle.net/21.15107/rcub_farfar_2667
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу